Article Text

Download PDFPDF
Telmisartan did not prevent recurrent stroke or major cardiovascular events

Statistics from Altmetric.com

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

S Yusuf

Dr S Yusuf, McMaster University, Hamilton, Ontario, Canada; yusufs@mcmaster.ca

STUDY DESIGN

Design:

randomised placebo-controlled trial with 2 × 2 factorial design (Prevention Regimen for Effectively Avoiding Second Strokes [PRoFESS]). ClinicalTrials.gov NCT00153062.

Allocation concealment:

concealed.*

Blinding:

blinded {patients, clinicians, data collectors, outcome assessors, safety committee, and data analysts}†.*

STUDY QUESTION

Setting:

695 centres in 35 countries worldwide.

Patients:

20 332 …

View Full Text

Footnotes

  • Source of funding: Boehringer Ingelheim; Bayer Schering Pharm; GlaxoSmithKline.